---
title: "iTeos Therapeutics"
#date: '`r paste("Date:",Sys.Date())`'
fontsize: 12pt
output: html_document
---

<style type="text/css">

body{ /* Normal  */
      font-size: 13px;
  }
}
h1.title {
  font-size: 28px;
  color: DarkBlue;
}
h1 { /* Header 1 */
  font-size: 20px;
  color: DarkBlue;
}
h2 { /* Header 2 */
    font-size: 16px;
  color: DarkBlue;
}

}
code.r{ /* Code block */
    font-size: 12px;
}
pre { /* Code block - determines code spacing between lines */
    font-size: 14px;
}
</style>

\





# **iTeos Therapeutics Corporate Profile (competitive strength):  ** 

Sames as Venn Therapeutics, iTeos only focuses on immuno-oncology. iTeos addresses key unmet needs in the following aspects in immuno-oncology: the inhibition of immune suppression in inflamed (hot) tumors and the increase of immunogenicity in non-inflamed (cold) tumors. These include:

(bullet points are ordered in their descending priority)  
• Adenosine A2A antagonist, preclinical development  
• TIGIT immune checkpoint blocking antibody, preclinical development  
• STING agonist, lead identification  

In their STING program, iTeos has begun a rational design strategy coupled to high throughput screening to develop small molecules agonists, **unrelated to classical dinucleotides agonists**.




# **Latest news: ** 

*June 20, 2018* :  
- Oversubscribed financing round led by new U.S. investor MPM Capital   
- Proceeds to support accelerated development of innovative next-generation immuno-oncology pipeline into the clinic and the company’s expansion into the U.S.  

*April 12, 2018*:  
iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR




#**Pipeline**  

<img src="timeline_pic.png" style="width:50%; height:70px">
<img src="./company_analysis_excel/iteos.jpg">





For more details, check the reference below.




# Reference 

https://www.iteostherapeutics.com/about-us/our-company  
https://www.iteostherapeutics.com/node/148
